Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Throat cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    41 result(s) found for: Throat cancer. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2016-004463-39 Sponsor Protocol Number: 221921 Start Date*: 2019-03-06
    Sponsor Name:Sahlgrenska University Hospital, Department of Internal Medicine/Respiratory Medicine and Allergology [...]
    1. Sahlgrenska University Hospital, Department of Internal Medicine/Respiratory Medicine and Allergology
    2. University of Gothenburg
    Full Title: Influence on cough and airway symptoms by oral capsaicin (capscium oleoresin ) – a phase II, randomised, placebo-controlled clinical study in patients with chronic idiopathic cough
    Medical condition: Chronic idiopathic cough
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004356-30 Sponsor Protocol Number: PCYC-1145-LT Start Date*: 2020-03-11
    Sponsor Name:Pharmacyclics Switzerland GmbH, an AbbVie company
    Full Title: Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10043515 Throat cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10054695 Waldenstrom's macroglobulinemia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008976 Chronic lymphocytic leukemia LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076596 Marginal zone lymphoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009944 Colon cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033604 Pancreatic cancer LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042080 Stomach cancer LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029473 Nodular (follicular) lymphoma LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041152 Small lymphocytic lymphoma, consistent with CLL (Working Formulation) LLT
    20.0 100000004870 10018799 GVHD LLT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10023400 Kidney cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) GR (Completed) CZ (Trial now transitioned) DE (Completed) ES (Ongoing) PL (Trial now transitioned) BE (Completed) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-024046-29 Sponsor Protocol Number: GEP 11/1010 Start Date*: 2013-05-28
    Sponsor Name:FNCLCC
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-001745-25 Sponsor Protocol Number: CC-486-NPC-001 Start Date*: 2015-01-22
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Multicenter, International, Single Arm Study to Assess the Safety and Efficacy of Single Agent CC-486 (Oral Azacitidine) in Previously Treated Subjects With Locally Advanced or Metastati...
    Medical condition: Locally advanced or metastatic nasopharyngeal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10028793 Nasopharyngeal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001373-70 Sponsor Protocol Number: ET20-076 Start Date*: 2020-04-01
    Sponsor Name:Centre Léon Bérard
    Full Title: IMMUNONCOVID-20 : A prospective, controlled, randomized, multicenter study to compare the efficacy of a chloroquine analog (GNS561), anti PD-1 (nivolumab) and anti-interleukine-6 receptor (tocilizu...
    Medical condition: Patients with advanced or metastatic cancer who have Sars-CoV-2 infection not eligible to a resuscitation unit
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003048-21 Sponsor Protocol Number: Uni-Köln-1667 Start Date*: 2014-03-10
    Sponsor Name:University of Cologne
    Full Title: CONTROLING INTESTINAL COLONIZATION OF HIGH-RISK PATIENTS WITH EXTENDED- SPECTRUM BETALACTAMASE PRODUCING ENTEROBACTERIACEAE (ESBL-E) – A RANDOMIZED TRIAL (CLEAR)
    Medical condition: Immunocompromised patients at high risk of bloodstream infections with colonizing bacteria.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10066481 Hematological malignancy LLT
    16.1 100000004865 10067862 Allogeneic stem cell transplantation LLT
    16.1 100000004870 10054990 Immunodeficiency secondary to organ transplantation LLT
    16.1 100000004870 10021458 Immunodeficiency secondary to transplantation chemotherapy LLT
    16.1 100000004870 10021452 Immunodeficiency secondary to chemotherapy (excl corticosteroids) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003392-32 Sponsor Protocol Number: 2014/VCC/0014 Start Date*: 2014-10-24
    Sponsor Name:Velindre NHS Trust
    Full Title: A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer
    Medical condition: Oropharyngeal cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031096 Oropharyngeal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) DE (Trial now transitioned) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-002217-59 Sponsor Protocol Number: 63623872FLZ3002 Start Date*: 2018-05-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, ...
    Medical condition: Influenza A Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) LV (Prematurely Ended) EE (Completed) LT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) SK (Prematurely Ended) HU (Prematurely Ended) BE (Completed) BG (Prematurely Ended) CZ (Prematurely Ended) PL (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-002016-28 Sponsor Protocol Number: 20040118 Start Date*: 2005-01-04
    Sponsor Name:Amgen
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduct...
    Medical condition: Oral mucositis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004856 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-000213-35 Sponsor Protocol Number: 20020402 Start Date*: 2005-08-05
    Sponsor Name:Swedish Orphan Biovitrum AB (publ.)
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (Recombinant Human Keratinocyte Growth Factor, rHuKGF) for the Reduct...
    Medical condition: Oral mucositis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004856 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) AT (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003953-16 Sponsor Protocol Number: OTO4008 Start Date*: 2016-04-05
    Sponsor Name:ÁREA DE ATENCIÓN INTEGRADA DE ALBACETE
    Full Title: A Phase IIIb study of the efficacy of dexamethasone in irreversible hearing loss prevention in subjects with Ototoxic Oncological Treatment. Otoprotection in cancer treatment.
    Medical condition: Cisplatin ototoxicity
    Disease: Version SOC Term Classification Code Term Level
    18.1 10013993 - Ear and labyrinth disorders 10033109 Ototoxicity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001634-26 Sponsor Protocol Number: RPH001BEV01 Start Date*: 2017-06-07
    Sponsor Name:TRPHARM
    Full Title: Phase I, Double Blind, Randomized, Parallel-Arm, Single-Dose, Pharmacokinetic and Safety Study of Bevacizumab-biosimilar (RPH-001) Compared to Bevacizumab-innovator (Avastin®, Roche) in Healthy Mal...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-003389-26 Sponsor Protocol Number: RG14-093 Start Date*: 2015-01-12
    Sponsor Name:University of Birmingham
    Full Title: Phase III randomised controlled trial Comparing Alternative Regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
    Medical condition: Oropharyngeal Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10031096 Oropharyngeal cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Temporarily Halted) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000999-11 Sponsor Protocol Number: MNPR-301-001 Start Date*: 2021-09-23
    Sponsor Name:Monopar Therapeutics Inc.
    Full Title: A Phase 2b/3, multicenter, randomized, double-blind, placebocontrolled study comparing the efficacy and safety of clonidine mucoadhesive buccal tablet to placebo to prevent chemoradiotherapy-induce...
    Medical condition: Chemoradiotherapy (CRT)-induced severe oral mucositis (SOM) in patients with oropharyngeal cancer (OPC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10028130 Mucositis oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002723-42 Sponsor Protocol Number: HH1222 Start Date*: 2013-09-11
    Sponsor Name:Rigshospitalet
    Full Title: Electrochemotherapy of Head and Neck Cancer
    Medical condition: Head and Neck Cancer. We would like to investigate the possible use of electrochemotherapy in recurrent head and neck cancer. Surgery and radiotherapy, with the possible addition of chemotherapy, c...
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004865 10068476 Electrochemotherapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003248-36 Sponsor Protocol Number: 61383082 Start Date*: 2011-09-30
    Sponsor Name:Central Military Hospital
    Full Title: The clinical significance of epigenetic factors research to refine the diagnosis, estimate prognosis and risk of recurrence after curative pancreatic cancer resection.
    Medical condition: The aim of the study to estimate frequence of epigenetics changes in pancreatic cancer and to assess the signidicance of apllication of the intravenous contrast agent during endosonography to bette...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10018065 - General disorders and administration site conditions 10016335 Feeling hot and cold LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037872 Rash NOS LLT
    14.0 10037175 - Psychiatric disorders 10032168 Other insomnia LLT
    14.0 10007541 - Cardiac disorders 10008481 Chest pain - cardiac LLT
    14.0 10017947 - Gastrointestinal disorders 10064907 Functional abdominal pain LLT
    14.0 10029205 - Nervous system disorders 10048324 Dizziness aggravated LLT
    14.0 10029205 - Nervous system disorders 10033777 Paraesthesia distal LLT
    14.0 10022891 - Investigations 10050786 Fasting blood glucose increased LLT
    14.0 10018065 - General disorders and administration site conditions 10022096 Injection site reaction NOS LLT
    14.0 10021881 - Infections and infestations 10034838 Pharyngitis NOS LLT
    14.0 10018065 - General disorders and administration site conditions 10016259 Fatigueability LLT
    14.0 10021428 - Immune system disorders 10020762 Hypersensitivity type I LLT
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10048412 Back pain aggravated LLT
    14.0 10021428 - Immune system disorders 10020756 Hypersensitivity reaction LLT
    14.0 10017947 - Gastrointestinal disorders 10028822 Nauseated LLT
    14.0 10047065 - Vascular disorders 10048347 Flushing aggravated LLT
    14.0 10029205 - Nervous system disorders 10024857 Loss of consiousness LLT
    14.0 10029205 - Nervous system disorders 10019218 Headache NOS LLT
    14.0 10040785 - Skin and subcutaneous tissue disorders 10037096 Pruritus NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003058-10 Sponsor Protocol Number: NADEJ201901 Start Date*: 2019-11-21
    Sponsor Name:VÝCHODOSLOVENSKÝ ONKOLOGICKÝ ÚSTAV, a.s.
    Full Title: Prospective, multicentre phase II study of de-escalation of primary chemoradiotherapy of squamous cell carcinoma of oropharynx (OPC) associated with human papilloma virus (HPV)
    Medical condition: Human Papillomavirus oropharyngeal squamous cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001034-35 Sponsor Protocol Number: RG_19-138 Start Date*: 2020-10-15
    Sponsor Name:University of Birmingham
    Full Title: Accelerating the Development and implementation of Personalised Treatments of DNA Damage Response agents and radiotherapy +/- immunotherapy for head and neck squamous cell cancer
    Medical condition: Head and neck squamous cell carcinoma (HNSCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067821 Head and neck cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-003990-89 Sponsor Protocol Number: Uni-Koeln-1707 Start Date*: 2015-05-12
    Sponsor Name:University of Cologne
    Full Title: Brentuximab vedotin or B-CAP in the treatment of older patients with newly diagnosed classical Hodgkin Lymphoma – a GHSG-NLG Intergroup Phase II trial –
    Medical condition: Treatment of older patients with newly diagnosed classical Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed) SE (Completed) DK (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-005395-35 Sponsor Protocol Number: GatesMRI-COD-01-T01-01 Start Date*: 2020-12-16
    Sponsor Name:Bill & Melinda Gates Medical Research Institute
    Full Title: A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban (Xarelto®) for high risk people with mild COVID-19
    Medical condition: Mild COVID-19 in people who are at high risk for moderate or severe disease due to age, body mass index (BMI) and comorbidities, many of which are also thrombotic risks.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 02:05:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA